Skip to main content
Journal cover image

Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405.

Publication ,  Journal Article
Lipsyc-Sharf, M; Zhang, S; Ou, F-S; Ma, C; McCleary, NJ; Niedzwiecki, D; Chang, I-W; Lenz, H-J; Blanke, CD; Piawah, S; Van Loon, K; Venook, AP ...
Published in: J Natl Cancer Inst
March 8, 2022

BACKGROUND: The incidence of young-onset colorectal cancer (yoCRC) is increasing. It is unknown if there are survival differences between young and older patients with metastatic colorectal cancer (mCRC). METHODS: We studied the association of age with survival in 2326 mCRC patients enrolled in the Cancer and Leukemia Group B and SWOG 80405 trial, a multicenter, randomized trial of first-line chemotherapy plus biologics. The primary and secondary outcomes of this study were overall survival (OS) and progression-free survival (PFS), respectively, which were assessed by Kaplan-Meier method and compared among younger vs older patients with the log-rank test. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated based on Cox proportional hazards modeling, adjusting for known prognostic variables. All statistical tests were 2-sided. RESULTS: Of 2326 eligible subjects, 514 (22.1%) were younger than age 50 years at study entry (yoCRC cohort). The median age of yoCRC patients was 44.3 vs 62.5 years in patients aged 50 years and older. There was no statistically significant difference in OS between yoCRC vs older-onset patients (median = 27.07 vs 26.12 months; adjusted HR = 0.98, 95% CI = 0.88 to 1.10; P = .78). The median PFS was also similar in yoCRC vs older patients (10.87 vs 10.55 months) with an adjusted hazard ratio of 1.02 (95% CI = 0.92 to 1.13; P = .67). Patients younger than age 35 years had the shortest OS with median OS of 21.95 vs 26.12 months in older-onset patients with an adjusted hazard ratio of 1.08 (95% CI = 0.81 to 1.44; Ptrend = .93). CONCLUSION: In this large study of mCRC patients, there were no statistically significant differences in survival between patients with yoCRC and CRC patients aged 50 years and older.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Cancer Inst

DOI

EISSN

1460-2105

Publication Date

March 8, 2022

Volume

114

Issue

3

Start / End Page

427 / 435

Location

United States

Related Subject Headings

  • Rectal Neoplasms
  • Progression-Free Survival
  • Oncology & Carcinogenesis
  • Middle Aged
  • Leukemia
  • Humans
  • Colorectal Neoplasms
  • Colonic Neoplasms
  • Antineoplastic Combined Chemotherapy Protocols
  • Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lipsyc-Sharf, M., Zhang, S., Ou, F.-S., Ma, C., McCleary, N. J., Niedzwiecki, D., … Ng, K. (2022). Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. J Natl Cancer Inst, 114(3), 427–435. https://doi.org/10.1093/jnci/djab200
Lipsyc-Sharf, Marla, Sui Zhang, Fang-Shu Ou, Chao Ma, Nadine Jackson McCleary, Donna Niedzwiecki, I-Wen Chang, et al. “Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405.J Natl Cancer Inst 114, no. 3 (March 8, 2022): 427–35. https://doi.org/10.1093/jnci/djab200.
Lipsyc-Sharf M, Zhang S, Ou F-S, Ma C, McCleary NJ, Niedzwiecki D, et al. Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. J Natl Cancer Inst. 2022 Mar 8;114(3):427–35.
Lipsyc-Sharf, Marla, et al. “Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405.J Natl Cancer Inst, vol. 114, no. 3, Mar. 2022, pp. 427–35. Pubmed, doi:10.1093/jnci/djab200.
Lipsyc-Sharf M, Zhang S, Ou F-S, Ma C, McCleary NJ, Niedzwiecki D, Chang I-W, Lenz H-J, Blanke CD, Piawah S, Van Loon K, Bainter TM, Venook AP, Mayer RJ, Fuchs CS, Innocenti F, Nixon AB, Goldberg R, O’Reilly EM, Meyerhardt JA, Ng K. Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. J Natl Cancer Inst. 2022 Mar 8;114(3):427–435.
Journal cover image

Published In

J Natl Cancer Inst

DOI

EISSN

1460-2105

Publication Date

March 8, 2022

Volume

114

Issue

3

Start / End Page

427 / 435

Location

United States

Related Subject Headings

  • Rectal Neoplasms
  • Progression-Free Survival
  • Oncology & Carcinogenesis
  • Middle Aged
  • Leukemia
  • Humans
  • Colorectal Neoplasms
  • Colonic Neoplasms
  • Antineoplastic Combined Chemotherapy Protocols
  • Aged